Company Filing History:
Years Active: 2020-2025
Title: Innovator Cheng Peng: Pioneering Research in Hepatitis B Treatment
Introduction
Cheng Peng is an esteemed inventor based in Suzhou, China, known for his significant contributions to pharmaceutical research. With two granted patents to his name, his work focuses primarily on compounds that offer potential treatment for viral infections.
Latest Patents
Cheng's latest patents revolve around the Dihydroisoquinoline compound, which is documented under two distinct patents. The first patent presents compositions containing a compound of general formula I, aimed at preventing or treating hepatitis B virus infection. The second patent elaborates on the compound of general formula I itself, highlighting its effectiveness in the same therapeutic context. These innovations mark a notable advancement in the fight against hepatitis B, showcasing Cheng's commitment to developing solutions for serious health challenges.
Career Highlights
Cheng Peng is currently affiliated with Suzhou Ark Biopharmaceutical Co., Ltd., where he engages in cutting-edge research in the field of biopharmaceuticals. His expertise in developing compounds that address viral infections positions him as a notable figure in the industry, and his innovative approach continues to contribute to advancements in medical science.
Collaborations
Throughout his career, Cheng has collaborated with several talented professionals, including Yang Zhou and Gang Zou. These partnerships have fostered an environment of innovation and progress, enhancing the research capabilities at Suzhou Ark Biopharmaceutical Co., Ltd. The collective efforts of these researchers amplify the impact of their work in the pharmaceutical sector.
Conclusion
Cheng Peng's innovative work in developing Dihydroisoquinoline compounds represents a significant milestone in the effort to combat hepatitis B virus infections. His patents not only demonstrate his inventive spirit but also highlight the potential for breakthroughs in treatment methods. Cheng's ongoing contributions to biopharmaceutical research signal a hopeful future for those affected by viral infections.